+86-571-85081802     info@multin.cn
API Grade Docetaxel Trihydrate Taxotere 148408-66-6
Home » Products » Pharmaceutical » API Grade Docetaxel Trihydrate Taxotere 148408-66-6

Contact Us

 Tel: +86-571-85081802
  Phone: +86-13655719091
 E-mail: info@multin.cn
  Add: Room 321,lingjun Mansion South,the 10th Chaowang Road,xiacheng District,hangzhou City,zhejiang Province China

API Grade Docetaxel Trihydrate Taxotere 148408-66-6

Share to:

API Grade Docetaxel Trihydrate Taxotere 148408-66-6
CAS:148408-66-6
MF: C43H53NO14.3H2O
MW: 861.929
EINECS: 642-361-2

  • CAS:148408-66-6
  • MT
  • 148408-66-6
  • CAS:148408-66-6

 API Grade Docetaxel Trihydrate Taxotere 148408-66-6 

Product name: Docetaxel Trihydrate

CAS No.:  148408-66-6

Apparence: White crystal Powder

MF:  C43H53NO14.3H2O

Purity: 99%

Appearance White or almost white crystalline powder




Top-Quality-Tenofovir-disoproxil-fumarate-cas-202138

                                          

111 

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel has an approved claim for treatment of patients who have locally advanced, or metastatic breast or non small-cell lung cancer who have undergone anthracycline-based chemotherapy and failed to stop cancer progression or relapsed.Administered as a one-hour infusion every three weeks generally over a ten cycle course, docetaxel is considered better than doxorubicin, paclitaxel and fluorouracil as a cytotoxic antimicrotubule agent.

 

1.It is a clinically well established anti mitotic chemotherapy medication (that is, it interferes with cell division).
2.It is used mainly for the treatment of breast, ovarian, and non-small cell lung cancer.
3.It has an FDA approved claim for treatment of patients who have locally advanced, or metastatic breast or non small-cell lung cancer who have undergone anthracycline based chemotherapy and failed to stop cancer progression or relapsed. An European approval docetaxel for use in hormone-refractory prostate cancer.
4.It is considered better than doxorubicin, paclitaxel and fluorouracil as a cytotoxic antimicrotubule.


 

Packing and Shipping:


packing

packing1


OUR PRODUCTS

HOT LINKS

Copyright  2020 ZHEJIANG MULTINPHARMA CO.,LTD All Rights Reserved  浙ICP备17013806号-1  |  Technology by www.leadong.com